![Dee Datta](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Dee Datta
Directeur Général chez Switch Therapeutics, Inc.
Postes actifs de Dee Datta
Sociétés | Poste | Début | Fin |
---|---|---|---|
Switch Therapeutics, Inc.
![]() Switch Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Switch Therapeutics, Inc. is an American biotechnology company that aims to treat a range of diseases affecting the central nervous system and systemic indications with significant unmet need. Switch is based in , and was founded by Dee Datta, who has been the CEO since incorporation. The company is pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science. The company's novel gene knockdown approach, the Conditionally Activated siRNA (CASI) platform, is based on technology developed by renowned researchers in the field of RNA and drug development from Caltech, Harvard Medical School, and City of Hope. | Directeur Général | 28/03/2023 | - |
Fondateur | - | - |
Historique de carrière de Dee Datta
Anciens postes connus de Dee Datta
Sociétés | Poste | Début | Fin |
---|---|---|---|
XOMA CORPORATION | Corporate Officer/Principal | 08/01/2018 | 31/08/2019 |
FORTY SEVEN, INC. | Corporate Officer/Principal | 01/07/2016 | 01/12/2017 |
Allozyne, Inc.
![]() Allozyne, Inc. Medical SpecialtiesHealth Technology Allozyne, Inc. operates as a biotechnology company that develops and manufactures pharmaceutical products. The firm focuses on manufacture of protein therapeutics for the medical need in autoimmune diseases and cancer. The company was founded by David A. Tirrell, Deepshikha Datta, and William A. Goddard, III in March 2004 and is headquartered in Seattle, WA. | Fondateur | 01/03/2004 | 01/01/2006 |
Corporate Officer/Principal | 01/03/2004 | 01/01/2006 | |
XOMA CORPORATION | Corporate Officer/Principal | - | - |
The Column Group LLC
![]() The Column Group LLC Investment ManagersFinance The Column Group LLC is a venture capital firm founded in 2005 by Peter Svennilson. The firm is headquartered in San Francisco. | Private Equity Investor | 07/12/2010 | - |
Formation de Dee Datta
California Institute of Technology | Doctorate Degree |
Stanford Graduate School of Business | Masters Business Admin |
Statistiques
Internationale
Etats-Unis | 8 |
Opérationnelle
Corporate Officer/Principal | 4 |
Founder | 2 |
Private Equity Investor | 1 |
Sectorielle
Health Technology | 5 |
Consumer Services | 3 |
Finance | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
XOMA CORPORATION | Health Technology |
Entreprise privées | 4 |
---|---|
Allozyne, Inc.
![]() Allozyne, Inc. Medical SpecialtiesHealth Technology Allozyne, Inc. operates as a biotechnology company that develops and manufactures pharmaceutical products. The firm focuses on manufacture of protein therapeutics for the medical need in autoimmune diseases and cancer. The company was founded by David A. Tirrell, Deepshikha Datta, and William A. Goddard, III in March 2004 and is headquartered in Seattle, WA. | Health Technology |
The Column Group LLC
![]() The Column Group LLC Investment ManagersFinance The Column Group LLC is a venture capital firm founded in 2005 by Peter Svennilson. The firm is headquartered in San Francisco. | Finance |
Forty Seven, Inc.
![]() Forty Seven, Inc. Pharmaceuticals: MajorHealth Technology Forty Seven, Inc. develops therapies that target cancer immune evasion pathways. It develops Hu5F9-G4, a monoclonal antibody against human CD47 that potentially has applications spanning multiple tumor types and treatment modalities. The company was founded by Irving L. Weissman, Ravi Majeti, Mark Chao and Jens-Peter Volkmer in 2014 and is headquartered in Menlo Park, CA. | Health Technology |
Switch Therapeutics, Inc.
![]() Switch Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Switch Therapeutics, Inc. is an American biotechnology company that aims to treat a range of diseases affecting the central nervous system and systemic indications with significant unmet need. Switch is based in , and was founded by Dee Datta, who has been the CEO since incorporation. The company is pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science. The company's novel gene knockdown approach, the Conditionally Activated siRNA (CASI) platform, is based on technology developed by renowned researchers in the field of RNA and drug development from Caltech, Harvard Medical School, and City of Hope. | Health Technology |